Frank Karbe
Vermögen: 647 325 $ am 31.05.2026
Vermögen: 647 325 $ am 31.05.2026
Mr. Frank L.
Karbe is a Chief Financial & Accounting Officer at Cidara Therapeutics, Inc. and an Independent Director at Phathom Pharmaceuticals, Inc. He is on the Board of Directors at Phathom Pharmaceuticals, Inc. and Navigen, Inc. Mr. Karbe was previously employed as a President, CEO, Secretary & Treasurer by Better Therapeutics, Inc., an Independent Director by Aduro BioTech, Inc., a President, CFO & Chief Accounting Officer by Myovant Sciences Ltd., a President by Myovant Sciences, Inc., a President by The Color Run LLC, an Independent Director by Arbutus Biopharma Corp., a Chief Financial Officer & Executive Vice President by Exelixis, Inc., and a Vice President-Healthcare Group by Goldman Sachs & Co. He also served on the board at Kolltan Pharmaceuticals, Inc.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 19.05.2026 | 67’500 ( 0.08% ) | 647 325 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| PHATHOM PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 25.04.2022 |
| CIDARA THERAPEUTICS | Finanzdirektor/CFO | 24.02.2025 |
Navigen, Inc.
Navigen, Inc. Pharmaceuticals: MajorHealth Technology Operates as a drug discovery and development company | Direktor/Vorstandsmitglied | - |
| Unternehmen | Position | Ende |
|---|---|---|
| BETTER THERAPEUTICS, INC. | Vorstandsvorsitzender | 14.03.2024 |
Myovant Sciences, Inc.
Myovant Sciences, Inc. Medical SpecialtiesHealth Technology Develops therapeutics for women''s health and prostate cancer | Präsident | 12.08.2021 |
| MYOVANT SCIENCES LTD. | Finanzdirektor/CFO | 12.08.2021 |
| CHINOOK THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 05.10.2020 |
| ARBUTUS BIOPHARMA CORPORATION | Direktor/Vorstandsmitglied | 01.01.2018 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 12 |
|---|---|
Exelixis, Inc.
Exelixis, Inc. Pharmaceuticals: MajorHealth Technology Operates as a cancer drug discovery company | Health Technology |
Arbutus Biopharma Corp.
Arbutus Biopharma Corp. Pharmaceuticals: MajorHealth Technology Develops novel therapeutics which targets viral diseases | Health Technology |
Aduro BioTech, Inc.
Aduro BioTech, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage immuno-oncology company, which focuses on the development of technology platforms for cancer | Health Technology |
Kolltan Pharmaceuticals, Inc.
Kolltan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures monoclonal antibody drugs | Health Technology |
Goldman Sachs & Co. LLC
Goldman Sachs & Co. LLC Investment Banks/BrokersFinance Provides brokerage services | Finance |
Navigen, Inc.
Navigen, Inc. Pharmaceuticals: MajorHealth Technology Operates as a drug discovery and development company | Health Technology |
Cidara Therapeutics, Inc.
Cidara Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Engages in the discovery, development, and commercialization of novel anti-infectives | Health Technology |
Myovant Sciences, Inc.
Myovant Sciences, Inc. Medical SpecialtiesHealth Technology Develops therapeutics for women''s health and prostate cancer | Health Technology |
The Color Run LLC
The Color Run LLC Movies/EntertainmentConsumer Services Operates as event management company | Consumer Services |
Myovant Sciences Ltd.
Myovant Sciences Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which provides women's health and prostate cancer solutions | Health Technology |
Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel treatments for gastrointestinal diseases and disorders | Health Technology |
Better Therapeutics, Inc.
Better Therapeutics, Inc. Medical SpecialtiesHealth Technology Develops prescription digital therapeutics for the treatment of cardiovascular and metabolic diseases | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen